Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Like several other biopharmas before it, UCB has turned to perhaps the most recognizable dermatologist in the U.S. to add ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Pharmacy benefit managers (PBMs) are up to bat in the perpetual blame game between PBMs and the pharmaceutical industry. | ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

With the threat of Trump administration's tariffs swirling and biopharma companies bracing for impact, many are announcing ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...

While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...